Sarah Jane Tribble, Kaiser Health News

Author's details

Name: Sarah Jane Tribble, Kaiser Health News
Date registered: September 13, 2017
URL: http://khn.org

Latest posts

  1. For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs — December 13, 2018
  2. Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist — October 26, 2018
  3. Drugmakers Play The Patent Game To Lock In Prices, Block Competitors — October 2, 2018
  4. Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making — September 11, 2018
  5. Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points — August 10, 2018

Author's posts listings

For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs

It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.

Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist

Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.

Drugmakers Play The Patent Game To Lock In Prices, Block Competitors

Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.

Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making

As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.

Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points

Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.

Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points

Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.

Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated

Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.

Explore the Archive